Novo is a holding company specializing in life science investor with a focus on creating long-term value.
Established in 1999, Novo Holdings is the holding company of the Novo Group and manages the Foundation's investment assets.
In addition to being the major shareholder in the Novo Group companies, Novo Holdings invests the wealth of the Foundation in two key categories: 1. Life Science Investments, which includes investing in life science companies at all stages of development; and 2. Financial Investments, which manages a diversified portfolio of equity and fixed income securities.
Working out of Copenhagen, San Francisco and Boston, Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
The purpose of the investments of Novo Holdings is both to grow the assets of the Foundation and to deliver a return that the Foundation can distribute for scientific, social and humanitarian purposes to improve the health and welfare of people.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 21, 2022
Doctor Anywhere
|
Series C | $38.80M | Health Care | Yes |
Aug 30, 2022
MedGenome
|
Series Unknown | $50M | Biotechnology | Yes |
Mar 30, 2022
Qure AI
|
Series C | $40M | Artificial Intelligence | Yes |
Jan 25, 2022
Metagenomi
|
Series B | $175M | Artificial Intelligence | — |
Aug 24, 2021
Doctor Anywhere
|
Series C | $65.70M | Health Care | — |